The Hyperfine Swoop is not a conventional MRI system in any meaningful sense. It is a portable, point-of-care brain imaging device that operates at 0.064T, can be wheeled to the patient's bedside in an ICU or emergency department without any room shielding, and produces neurological images through a conventional wall outlet. The entire premise of the system is that brain imaging should go to the patient, not the patient to the imaging suite. For hospitals and health systems with high-acuity neurological patient populations, the financing conversation around the Swoop is less about siting and more about the clinical program it enables and the operational cost it displaces.
The Hyperfine imaging platform is a genuinely different category than the superconducting MRI systems that make up most of the MRI financing market. Buyers evaluating the Swoop are not comparing it to a 1.5T outpatient system; they are evaluating it as a neuro critical care tool against the cost and logistics of transporting critically ill patients to the radiology department for conventional MRI. That framing changes the financial analysis, and the financing structure follows from it.
What the Swoop Actually Is: Point-of-Care Neurology
The Swoop operates at 64 mT (0.064T), a field strength that is dramatically lower than any conventional MRI system but sufficient for brain imaging applications including hemorrhage detection, midline shift assessment, hydrocephalus monitoring, and post-surgical brain evaluation. The system requires no RF shielding, no cryogens, no dedicated electrical infrastructure, and no special room preparation. It runs on 110V standard power and can be wheeled from room to room on its integrated cart.
The primary clinical applications where the Swoop has been deployed involve patients who cannot be safely or practically transported to the conventional MRI suite: ICU patients on ventilators, patients with intracranial monitoring devices, trauma patients in the emergency department, and patients in neurocritical care units where transport risk is significant. For those populations, the Swoop provides neurological imaging that was previously unavailable or accessible only at considerable logistical cost and patient risk.
At 0.064T, the Swoop produces images that are appropriate for the specific diagnostic questions it is designed to address. It does not replace a 1.5T or 3T system for broad clinical MRI applications. That clinical scope should be clearly understood before a financing commitment is made, because the ROI calculation depends on a realistic assessment of how frequently the system will be used for its intended clinical purpose. For programs where that use case is real and regular, the financing math can be favorable. For programs where the use case is occasional or speculative, it may not be.
Financing the Hyperfine Swoop: Process and Structure
The Swoop's acquisition price is significantly lower than conventional MRI systems, which changes the documentation requirements substantially. Many Swoop transactions fall below the application-only threshold, making approval faster and simpler than for a conventional MRI acquisition. For qualified buyers, application-only financing avoids the full financial documentation requirement, and approval can come in days rather than weeks.
For buyers whose total financed amount exceeds the application-only threshold, or who are financing multiple Swoop units simultaneously, the full underwrite applies. The documentation is the same as for any MRI acquisition: two years of business tax returns, three months of bank statements, and a debt schedule. Hospital and health system buyers typically involve a capital request and finance committee process that differs from the outpatient practice acquisition workflow, and we accommodate both timelines.
Structure choices are simpler at the Swoop's price point. A term loan with a dollar buyout is the most common structure, given the modest monthly payment at this acquisition price. A fair-market-value lease is available and may make sense for hospital buyers who prefer to keep capital equipment off the balance sheet under their operating lease accounting treatment. Term lengths typically run 36 to 60 months.
The Financial Case for Point-of-Care Brain Imaging
The financial case for the Swoop in a hospital or health system context comes down to two numbers: the cost of transport for critically ill patients to the conventional MRI suite, and the number of times per month that the Swoop prevents that transport by bringing imaging to the bedside. Transport of an ICU patient for conventional MRI involves nurse time, respiratory therapy coverage, monitoring equipment, and real safety risk. If the Swoop prevents a meaningful number of those transports per month, the labor and risk savings can offset the debt service cost substantially.
That analysis is site-specific: it depends on the patient census, the acuity of the neurological population, and the current transport workflow. We encourage buyers to run the numbers for their own program before committing to a financing amount, because the ROI case is strongest when it is grounded in actual patient volume rather than projected utilization. If the program is clinical research rather than routine clinical care, the analysis shifts to grant funding and research overhead rather than operational cost displacement.
For hospital and health system buyers, the capital approval process for the Swoop often involves clinical champions, finance, and administration in a structured review. We are prepared to support that process with financing analyses and documentation that fit a health system capital committee's requirements rather than an outpatient practice approval workflow.
The Portable MRI Market and Where the Swoop Sits
The portable MRI category is new in clinical terms, with Hyperfine's Swoop being the first FDA-cleared point-of-care MRI system for clinical use. The technology is part of a broader movement toward portable imaging platforms that bring diagnostic capability to wherever the patient is rather than the reverse. That movement is particularly relevant in settings where patient transport is a safety risk, an operational burden, or simply logistically impossible.
The Swoop sits alongside other emerging point-of-care technologies in the capital planning landscape, but its imaging modality, brain MRI, is unique in the portable category. There is no other FDA-cleared portable MRI competitor at the time of writing, which means the clinical use case determination comes down to whether point-of-care brain MRI, at 0.064T, is clinically useful enough for the buyer's specific patient population to justify the acquisition. For the programs that have reached that conclusion, the financing is available and the process is straightforward.
Hyperfine Swoop Financing Questions
- Is the Swoop financeable as medical equipment even though it operates at a very low field strength?
Yes. The Swoop is FDA-cleared as a class II medical device and is financed as medical imaging equipment. Its field strength does not affect financing eligibility; what matters is the FDA clearance status and the acquisition price. - Can hospitals finance multiple Swoop units on a single facility?
Yes. Multi-unit acquisitions on a single facility are financed as a single transaction with one underwriting review. The total financed amount determines whether you are in application-only or full underwrite territory. Hospital buyers often acquire more than one unit to cover multiple ICU pods or clinical units. - Is Hyperfine's service and warranty program robust enough for hospital requirements?
Hyperfine offers a service contract and warranty program for the Swoop. Hospital buyers should confirm the specific contract terms, response times, and loaner availability with Hyperfine's service organization before closing. The service contract should be included in the total project budget. - Does grant funding or research funding affect the financing structure?
If part of the acquisition cost is covered by a grant or research budget, the financed amount is reduced accordingly. The financing covers the non-grant portion. Research institutions should coordinate the grant timing with the financing commitment to avoid closing the loan before grant funds are confirmed available. - What is the typical term length for a Swoop acquisition?
36 to 60 months is typical. Shorter terms at the Swoop's price point have manageable monthly payments and align with a technology refresh cycle that may see hardware updates from Hyperfine as the platform matures.
Finance Your Hyperfine Swoop
Point-of-care brain imaging at the bedside represents a real clinical and operational advance for neuro critical care programs. If your program has determined that the Swoop is the right tool for your patient population, the financing is available and the process is simpler than for a conventional MRI. Share your program details and timeline and we will put together a financing option that fits.